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Abstract 24 
Monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple 25 
myeloma (SMM) are precursor conditions of symptomatic multiple myeloma (MM).  26 
Diagnostic principles are aimed at excluding MM requiring therapy, other conditions 27 
associated with paraproteins that may require different management, and risk stratifying 28 
patients for the purposes of tailored follow up and investigation.  The IMWG have recently 29 
published a revised definition of MM, that singles out a small group of patients with SMM 30 
who are at very high risk of progression and organ damage; such patients are now included 31 
under the definition of MM, and recommended to start anti-myeloma treatment.  32 
Furthermore, the recently published NICE guideline recommends cross sectional imaging 33 
techniques in place of skeletal survey.  These recent recommendations are discussed, and 34 
practical guidance for investigation and management presented.  35 
 36 
Introduction 37 
Monoclonal gammopathy of undetermined significance (MGUS) describes the presence of a 38 
serum monoclonal protein (paraprotein) without other evidence of multiple myeloma 39 
(MM), Waldentrom’s macroglobulinaemia (WM), amyloidosis or other lymphoproliferative 40 
disorder[1]. MGUS is thought to consistently precede the development of MM[2],  but not 41 
all patients with MGUS have the same risk of progression to MM. Many paraproteins are 42 
picked up incidentally and the challenge is how best to manage these patients whilst 43 
avoiding over investigation and/or incurring undue anxiety[3]. Risk models for progression 44 
can be incorporated into management algorithms for these patients. 45 
 46 
Smouldering myeloma (SMM) is an intermediate stage between MGUS and symptomatic 47 
MM[4].  Patients with SMM have a higher initial risk of progression compared to MGUS 48 
patients but risk reverts to MGUS levels after 10 years. Median time to progression is 49 
around 4.8 years[5].  SMM patients lack evidence of end organ damage, but a small 50 
proportion may warrant treatment on the basis of high risk biomarkers[6]. 51 
Epidemiology and pathophysiology 52 
The overall risk of progression of MGUS is approximately 1% per year[7], and remains 53 
unchanged over many years although many are elderly and will die from unrelated 54 
conditions[8]. Prevalence increases with age (3.2% over 50years), is higher in males and in 55 
Africans[9][10]. IgG is the commonest subtype (68.9%)[11]. MGUS is associated with 56 
diverse conditions including autoimmune and inflammatory conditions, liver disease, bone 57 
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marrow and organ transplantation[12][13]. The aetiology is unclear, suggested 58 
predisposing factors include family history of haematological malignancy, 59 
immunosuppression, radiation exposure and pesticides[14, 15]. SMM has a similar age of 60 
presentation as MGUS and symptomatic MM (60-70years), and is most commonly IgG 61 
(74%) or IgA (22.5%) [5][16].  62 
 63 
Founder genetic events in MM such as chromosomal translocation into the IgH gene loci 64 
and hyperdiploidy are present in MGUS.  Secondary genetic lesions occurring in sub-clones 65 
that compete for dominance may lead ultimately to clonal progression and expansion of 66 
certain “fitter” sub clones.  Common secondary events that are associated with the 67 
progression to symptomatic MM include point mutations in oncogenes (eg. N-RAS, K-RAS, 68 
TRAF3, p53), MYC up regulation by a variety of mechanisms, and chromosome 1 imbalance  69 
(1q gain or 1p loss).  A progressive increase in the incidence of copy number abnormalities 70 
and epigenetic modifications may occur [17] [18]. 71 
Definition of MGUS 72 
All criteria must be met: 73 
1. Serum monoclonal protein <30 g/L  74 
2. Clonal bone marrow (BM) plasma cells (PC) <10%,  75 
3. Absence of end-organ damage (hypercalcemia, renal insufficiency, anaemia, and 76 
bone lesions) [19]. 77 
MGUS Related Disorders and associated risks   78 
MGUS can be associated with other clinically significant conditions, listed in Table 1 [20], 79 
including AL amyloidosis, MGUS of renal significance (MGRS), type I and II 80 
cryoglobulinaemia, cold agglutinin disease and autoimmune neuropathies, the latter 81 
usually caused by autoantibody activity of an IgM paraprotein. Other rare diseases 82 
associated with monoclonal gammopathy include POEMS syndrome, scleromyxoedema, 83 
acquired Fanconi syndrome and Schnitzler syndrome [21, 22].  Individuals with MGUS have 84 
an increased risk of osteoporosis, venous/arterial thrombosis, infections, as well as an 85 
increased risk of developing myeloid and non-haematological malignancies [23] [24] [25].  86 
Definition of Smouldering MM including recent revisions 87 
In 2003 IMWG developed the first international consensus guidelines that classified SMM 88 
as BMPCs ≥10% and/or paraprotein (PP) ≥30 g/L) and critically the absence of CRAB 89 
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features (high calcium, haemoglobin 2g/dL below normal or <10 g/dL, lytic bone lesions or 90 
osteoporosis with compression fractures, symptomatic hyperviscosity, amyloidosis, or >2 91 
bacterial infections/12 months) [16].  As there was no evidence that treatment of 92 
asymptomatic SMM patients altered the natural disease history or improved long term 93 
outcomes, treatment was withheld unless progression occurred as defined by end organ 94 
damage.    95 
Revised criteria 96 
It became clear that some SMM patients are at very high risk of progression to symptomatic 97 
MM[18], moreover, progression was associated with marked morbidity. Hence, work was 98 
done to identify patients at ultra high risk (approximately 80%) of progression within 2 99 
years. Three markers identify patients at ultra high risk of progression (80% over 2 years) 100 
[6]:   101 
Additional new criteria for diagnosis of myeloma (Table 2)  102 
• Bone marrow plasmacytosis 103 
BMPCs of ≥60% (present in <5% of patients) carries a very high risk of progression to MM 104 
(>80% within 2 years)[26, 27], and is thus now considered a MM defining criterion.  105 
 106 
• Serum Free Light Chains 107 
High serum free light chains are a risk factor for progression in SMM [28], and SFLC ratio of 108 
>100 carries a 2-year progression risk of 72%[29], and is now a MM defining criterion.   109 
 110 
• Focal lesion/s on MRI 111 
MRI is now recommended for screening in SMM (see below). Patients with >1 focal lesion 112 
on MRI had a 70% risk of progression at 2 years)[30], findings subsequently confirmed [31, 113 
32].  Thus >1 focal lesion on MRI is now a MM defining criterion.  For patients with solitary 114 
bone lesions, data are less clear and regular (3-6 monthly) follow up by MRI is 115 
recommended. 116 
 117 
Table 2 summarises these new MM defining features, for which anti-MM treatment is 118 
recommended. Alongside these recommendations, revised definitions of organ damage 119 
have also been produced (Table 3). The term symptomatic MM should now be dropped, in 120 
favour of MM, to include asymptomatic patients who require treatment on the basis of one 121 
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or more MM defining criteria.  Hence SMM, previously used to refer to “symptomatic MM” 122 
should now be used exclusively to refer to smouldering MM, or asymptomatic MM.  123 
Risk factors for Progression in MGUS  124 
Presenting features and dynamics of the clone during follow up are helpful predictors of 125 
progression. Recognised risk factors include: 126 
a. Level of the monoclonal protein [33].  127 
b. Level of BMPCs (>5%)[34].   128 
c. Rise in paraprotein over time [35]. 129 
d. Abnormal SFLC ratio [36].    130 
e. Biological characteristic of the MGUS clone, higher for IgA/IgM than for IgG.  [11, 131 
33].  132 
Fluorescent-in-situ-hybridisation (FISH) defined abnormalities including recurrent 133 
primary IgH translocations and hyperdploidy are found in MGUS [37], but it is unclear if 134 
specific abnormalities eg. del(17p) are predictive of progression to MM. 135 
Risk models in MGUS 136 
Patients are risk stratified using clinical variables identified in epidemiological studies, and 137 
two main prognostic models are the Mayo clinic model, and the PETHEMA group or 138 
Spanish model (Table 4).  [36] [38].   139 
Risk Stratification Models in SMM 140 
The main risk models for SMM reflect those in MGUS (Table 4).  The Mayo clinic model 141 
included abnormal SFLC ratio, paraprotein level and BM plasmacytosis, while the Spanish 142 
group used a flow cytometry based model with two independent variables [39].  143 
Need for new risk models in SMM 144 
Revision of diagnostic criteria for MM that remove the ultra high risk SMM patients 145 
requires a re-evaluation of our risk models for SMM.  Genetic abnormalities [deletion 17p, 146 
t(4;14)] or gene expression signature may be important [31, 40, 41], as may PET-CT 147 
findings [42].  The presence of Bence Jones proteinuria (especially >500mg/24 hours) or 148 
rising paraprotein (evolving SMM) may also impart greater risk of progression [43]. 149 
Immunophenotype,  circulating plasma cells, a high PC proliferative rate have also been 150 
implicated [31].  All these need to be studied in larger patient cohorts to assess their wider 151 
applicability. 152 
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Diagnosis of MGUS 153 
The major aim of investigating these patients is to distinguish between MGUS, SMM and 154 
MM requiring treatment.  The commonest reason for assigning a diagnosis of SMM (rather 155 
than MGUS) is the presence of ≥10% plasma cells in the bone marrow.  For IgM and light 156 
chain only conditions, the equivalent is called smouldering WM, and idiopathic Bence Jones 157 
proteinuria, respectively. It is also important to differentiate MGUS of truly no clinical 158 
significance from MGUS associated with amyloidosis, Waldenstrom’s macroglobulinaemia  159 
(WM) and other lymphoid neoplasms. Symptoms should also be sought for the rarer 160 
disorders associated with a paraprotein e.g. POEMS syndrome. (Table 1) 161 
 162 
All patients require history and examination, full blood count, renal function, total protein, 163 
serum calcium, serum and urine protein electrophoresis with immunofixation and serum 164 
free light chains.  A bone marrow aspirate and trephine biopsy (BMAT) should be 165 
performed when serum PP ≥ 15g/L, if non IgG MGUS, abnormal SFLC ratio (> 10 or < 0.10), 166 
or if diagnosis of MGUS is in doubt. All patients with suspected myeloma (paraprotein > 167 
30g/l or bone marrow plasma cells >10%) need cross-sectional imaging as per recent NICE 168 
guidelines: whole body MRI as first line or whole body low dose CT. [50] 169 
 170 
For high risk MGUS patients (Mayo clinic model), a skeletal survey should be carried out (or 171 
a CT chest abdomen and pelvis in IgM MGUS). MRI or PET-CT imaging is not recommended 172 
outside the context of a clinical trial [44].  173 
Management of MGUS  174 
Clinical trial results show no benefit for early intervention, and the risk of progression to 175 
MM is low, thus current management is ‘watch and wait’ [45].  As risk of progression does 176 
not change over time lifelong follow up is recommended, with monitoring tailored to 177 
patient’s risk of progression, co-morbidities and life expectancy.  178 
 179 
Risk stratification of patients (Mayo clinic model) into low, intermediate and high risk 180 
MGUS aids counselling and follow up [46].  Current practice will vary from centre to centre. 181 
Based on currently available evidence and guidelines a reasonable approach is: 182 
Low risk: SS and BM not required, monitor every 6 months for 2 years then 1-2yrly if 183 
stable. Monitoring can be done in primary care and should include patient review, blood 184 
count, renal function, calcium, and paraprotein level.  185 
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Intermediate or high risk: SS and BM are mandatory, review and monitor as above every 6 186 
months for 2 years then annually for life.   Follow up should include history and 187 
examination, full blood count, renal function, calcium and paraprotein. Monitoring should 188 
be initially in secondary care, but after 5 years, primary care monitoring is reasonable.  189 
Although the risk of progression in patients with light chain only MGUS is relatively low 190 
(0.3% per year), there is a considerable risk of developing renal disease, hence 6-monthly 191 
follow up is recommended [11].  Finally, MGUS patients with elevated SFLC should be 192 
monitored for development of amyloidosis or MGRS, hence measurement of NT-proBNP 193 
and urine albumin at follow up is recommended [19].  194 
 195 
A BMAT +/- skeletal survey is always indicated if features suggestive of end organ damage 196 
develop or if >25% increase in PP levels occurs over a three month period (minimum 197 
5g/L).  Diagnostic work up and management plan should be altered according on age and 198 
co-morbidities (Figure 1).  For example in a person of advanced age with limited life 199 
expectancy it may be reasonable to omit SS and BMAT from the work up or not to 200 
undertake regular monitoring of the paraprotein level. Whichever risk group a patient falls 201 
into, it is important to provide information and counselling as the diagnosis may lead to 202 
anxiety and fears for the future. MyelomaUK provide written information and telephone 203 
advice: 204 
http://www.myeloma.org.uk/information/myeloma-uk-publications-list/other-related-205 
conditions/mgus-infosheet/ 206 
Diagnostic Investigations for SMM  207 
Investigations are aimed at differentiating SMM from symptomatic MM requiring 208 
treatment.  All patients need baseline blood counts, renal function, serum calcium and total 209 
protein, serum and urine protein electrophoresis with immunofixation and serum free light 210 
chains.   Risk stratification of SMM may be useful, eg. the Mayo clinic model.  All patients 211 
with a paraprotein >30g/L and/or SFLC ratio >8 should be considered for further testing 212 
with BM and imaging. As per NICE guidance, skeletal survey is no longer sufficient and 213 
cross-sectional imaging is recommended, with the choice of MRI, low-dose whole-body CT 214 
or PET-CT being made according to local practice [47].   215 
Treatment for SMM  216 
Historical studies have shown no advantage to initiating treatment for patients with SMM, 217 
largely due to lack of efficacy and high toxicity of regimens used.[48] [49][50].   Recently, a 218 
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randomised trial has indicated, for the first time, that treatment in SMM can improve 219 
outcomes. This Phase III trial used flow cytometry to identify high risk patients and 220 
prospectively randomised them to receive treatment with lenalidomide and 221 
dexamethasone versus observation only.  With median follow-up of 40 months, treated 222 
patients had significantly longer time to progression (median not reached vs. 21 months) 223 
and overall survival (3-year survival 94% vs. 80%) [51]. Drawbacks of the study are the 224 
criteria used to risk stratify, and the unexpectedly high rate of death in the control arm. 225 
Several trials are currently evaluating new drugs and strategies in high risk SMM, and such 226 
patients should be considered for entry into clinical trials otherwise observation still 227 
remains standard of care. 228 
Monitoring patients with SMM 229 
The risk of progression in SMM is highest in the first years after diagnosis, maximal in the 230 
first two years, and reducing over the next few years. Hence, the monitoring needs to be 231 
more frequent soon after diagnosis and can become less frequent 5 years after diagnosis.  232 
There are no formal prospective studies of monitoring in SMM.  As per NICE guidelines, 233 
patients should be monitored every 3 months initially [47].  Pragmatically, a reduced 234 
frequency of monitoring may be adopted after 2 years, depending on risk (Figure 2). 235 
Monitoring should include assessment of CRAB symptoms, FBC, renal function, bone 236 
profile, immunoglobulins, serum protein electrophoresis and SFLC if appropriate [47]. High 237 
risk patients, those with a rising paraprotein or new symptoms and those with a single 238 
focal lesion on MRI may need repeat imaging or bone marrow examinations.    239 
Conclusion and Future Directions 240 
MGUS is associated with a risk of progression to MM and a variety of other clinically 241 
significant conditions. Diagnostic work up of suspected MGUS patients should seek 242 
evidence of these.  Risk stratification models can help with estimating risk of progression 243 
and, together with patient-specific factors, planning follow-up.   244 
 245 
SMM is an area where on-going research is re-defining risk boundaries with implications 246 
for monitoring and treatment.  As new factors for progression are identified, some patients 247 
will now be reclassified as MM requiring treatment, and there is a suggestion that early 248 
treatment of high risk SMM may be of benefit.   While MM remains incurable, here is 249 
insufficient evidence, however, to recommend routine treatment of these asymptomatic 250 
patients, or indeed to indicate which treatment is the best.  Progression to MM may not the 251 
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only important end point for treatment of SMM patients as pre-emptive therapy may 252 
promote the earlier out-growth of resistant disease, making the treatment of truly 253 
symptomatic disease more difficult.  Genetics clearly define outcomes in MM, and may also 254 
impact outcomes of therapy in SMM.  All these remain important questions to be addressed 255 
in prospective trials to refine our approach to SMM and guide treatment, meanwhile 256 
current guidance is confined to monitoring [47].  257 
 258 
259 
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Tables 
Table 1. M-protein related disorders (other than AL amyloidosis) adapted 
21
  
Disorder Clinical features and diagnostic tests 
Light chain deposition 
disease (LCDD) 
Usually kappa light chain, presenting with albuminuria and 
nephrotic syndrome  
POEMS syndrome Majority IgG lambda 
Peripheral neuropathy 
Organomegaly (liver, spleen, lymphadenopathy) 
Skin changes (cherry angiomata, changes in texture and 
pigmentation, alterations in body hair) 
Endocrinopathy (pancreatic, adrenal, gonadal, paarhyroid, pituitary) 
Ascites, pleural effusions, peripheral oedema 
Pappiloedema 
Sclerotic bone lesions 
Thrombocytosis, polycythaemia, thrombotic diathesis 
Elevated circulating vascular endothlial growth factor 
Acquired Fanconi 
syndrome 
Tubular proteinuria, glycosuria, amino aciduria. acidosis, 
hypophosphatemia 
Renal failure, osteomalacia 
Almost all kappa light chain 
Cryglobulinaemia Vasculitis, peripheral neuropathy, fatigue, renal failure, 
purpuric rashes, Raynaud’s phenomenon, leg ulcers, 
acrocyanosis 
Scleromyxoedema Diffuse skin thickening, obstructive lung disease, pulmonary 
hypertension 
Usually IgG lambda 
Schnitzler Syndrome Chronic neutrophilic urticarial dermatosis 
Arthralgia, bone pain, lymph nodes, liver, spleen enlarged 
Usually IgM kappa 
Xanthomatosis Cutaneous xanthoma lesions (yellow papules) 
Usually IgG 
Cold agglutinin disease Haemolysis, Raynaud’s phenomenon, acrocyanosis 
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Table 2: Definition of multiple myeloma, incorporating recent revisions 
6 
 
Clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary 
plasmacytoma* and any one or more of the following myeloma defining events or any 
one or more of the following biomarkers of malignancy. 
 
Myeloma defining events: 
Evidence of end organ damage that can be attributed to the underlying plasma cell 
proliferative disorder as follows: 
• Hypercalcaemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit 
of normal or >2.75 mmol/L (>11 mg/dL) 
• Renal insufficiency: creatinine clearance <40 mL/min† or serum creatinine >177 
μmol/L (>2 mg/dL) 
• Anaemia: haemoglobin value of >20 g/L below the lower limit of normal or a 
haemoglobin value <100 g/L 
• Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT‡ 
 
Biomarkers of malignancy: 
•  Clonal bone marrow plasma cell percentage* ≥60% 
• Involved:uninvolved serum free light chain ratio§ ≥100 
• >1 focal lesions on MRI studies¶ 
 
Definition of smouldering multiple myeloma 
Both criteria must be met: 
• Serum monoclonal protein (IgG or IgA) ≥30 g/L or urinary monoclonal protein ≥500 
mg/24h and/or clonal bone marrow plasma cells 10–60% 
• Absence of myeloma defining events including biomarkers of malignancy or 
amyloidosis 
 
‡PET-CT=1⁸F-fluorodeoxyglucose PET with CT.  
*Clonality should be established by showing κ/λ-light-chain restriction on flow 
cytometry, immunohistochemistry, or immunofluorescence. Bone marrow plasma cell 
percentage should preferably be estimated from a core biopsy specimen; in case of a 
disparity between the aspirate and core biopsy, the highest value should be used.  
†Measured or estimated by validated equations.  
‡If bone marrow has less than 10% clonal plasma cells, more than one bone lesion is 
required to distinguish from solitary plasmacytoma with minimal marrow involvement.  
§These values are based on the serum Freelite assay (The Binding Site Group, 
Birmingham, UK). The involved free light chain must be ≥100 mg/L.  
¶ Each focal lesion must be 5mm or more in size 
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Table 3. New Definitions of organ damage
6 
Myeloma bone disease 
One of PET-CT, MRI or low-dose whole body CT (depending on local practice) to be used at 
diagnosis in suspected smouldering myeloma. The detection of one or more sites of 
osteolytic bone destruction (>5mm) on PET-CT or low-dose whole-body CT meets the 
criteria for multiple myeloma requiring treatment. Osteoporosis and vertebral compression 
fractures alone are no longer sufficient for a diagnosis of myeloma. This is to avoid over 
diagnosing many elderly people with MGUS and osteoporosis.  
Definition of renal failure 
The 2003 IMWG criteria used a fixed creatinine level (> 173umol/L) to define renal 
insufficiency.  New recommendation is to use measured or estimated GFR of <40ml/min 
instead for CRAB criteria.  Only renal failure caused by light chain cast nephropathy is 
regarded as a myeloma defining event. A renal biopsy may be needed to exclude other 
causes of renal failure. 
Bone marrow plasmacytosis 
Either clonal BMPC ≥10% or biopsy proven plasmacytoma required for the diagnosis of 
MM.  
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Table 4.  Risk models for MGUS, and for SMM 
 
MGUS 
Model and risk factors Number of factors Progression risk 
Mayo Clinic Model [35] 
- non-IgG isotype 
- M-protein ≥15g/L 
- abnormal SFLC ratio 
 
0 
1 
2 
3 
At 20 years 
5% 
21% 
37% 
58% 
PETHEMA model based on flow 
cytometry of bone marrow 
[338] 
- Abnormal phenotype 
(aberrant plasma cells) 
- DNA aneuploidy 
 
 
0 
1 
2 
At 5 years 
 
2% 
10% 
46% 
SMM 
Mayo Clinic Model [26] 
- abnormal SFLC ratio 
(<0.125 or > 8) 
- BM PCs ≥10% 
- PP ≥30g/L 
 
 
1 
2 
3 
At 5 years 
 
25% 
51% 
76% 
PETHEMA model based on  
flow cytometry [40] 
- ≥95% abnormal bone 
PC/total BMPC 
- Immuneparesis 
 
 
0 
1 
2 
 
At 5 years 
4% 
46% 
72% 
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Figure 1. Algorithm for investigation and management of patients with suspected Monoclonal Gammopathy 
of Undetermined Significance (MGUS)  
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   Laboratory findings suspicious of MM or MGUS   
- Raised ESR/PV  
- Unexplained anaemia, renal failure or hypercalcaemia  
- Raised total protein/globulin 
- Immunoparesis of uninvolved Igs 
 
Risk Stratification 
MAYO Clinic Model 
a) BMPC > 10% 
b) PP > 30g/L 
c) SFLC ratio > 8 or < 
0.125 
 
MGUS 
Serum PP < 30g/L 
BMPC < 10% 
No end organ damage 
Diagnostic Work-Up 
- History and examination for symptoms/signs of MM/LPD/amyloidosis/plasmacytoma 
- FBC, U+E, Calcium 
- Immunoglobulins, serum electrophoresis with immunofixation, paraprotein quantification 
- Urine electrophoresis and immunofixation, quantification of Bence Jones protein (BJP) 
- Serum Free Light Chains 
- Radiological screening (skeletal survey*, cross-sectional imaging**: MRI spine+pelvis, CT-PET, 
or low dose whole-body CT) 
- BM Aspirate and Biopsy*** 
SEE SEPARATE MGUS 
GUIDELINE AND 
ALGORITHM 
Smouldering Myeloma (SMM) 
Serum PP ≥ 30g/L 
AND/OR clonal BMPC ≥ 10% 
OR urinary BJP ≥ 500mg/24hrs 
No CRAB criteria and no 
myeloma defining events 
Myeloma needing treatment  
Clonal plasma cells in bone 
marrow ≥10% or biopsy proven 
plasmacytoma 
AND any CRAB criteria 
OR a myeloma defining event 
- BMPC ≥60 % 
- ≥ 2 focal lesions on MRI or 
PET-CT 
- Abnormal SFLC ratio (≥ 100 
or < 0.01) 
 
SEE SEPARATE MYELOMA 
TREATMENT GUIDELINES 
  
INTERMEDIATE RISK SMM 
2 Risk Factors 
50% risk of progression at 5 
years 
Observe every 3 months for 2 
years then 6-monthly for 5 years  
Consider discharge to GP after 5 
years if stable 
 
HIGH RISK SMM 
3 risk factors 
70% risk of progression at 5 
years 
Consider entry into a clinical 
trial 
Observe every 3 months for 5 
years  
Consider discharge to GP after 
5 years if stable 
 
LOW RISK SMM 
1 risk factor 
25% risk of progression at 
5 years 
Follow up every 3 months 
for 1 year, then 6-12 
monthly if stable 
Consider re-defining as 
MGUS-like and 
discharging to GP if no 
progression after 5 years 
* for high risk MGUS  
** if pp>30 or LC ratio >8, choice of technique according to local practice 
*** Required if non-IgG MGUS, pp ≥15g/L   
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